Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Assets (2020 - 2025)

Historic Assets for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $494.9 million.

  • Cytek Biosciences' Assets rose 75.18% to $494.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $494.9 million, marking a year-over-year increase of 75.18%. This contributed to the annual value of $499.5 million for FY2024, which is 101.99% up from last year.
  • Cytek Biosciences' Assets amounted to $494.9 million in Q3 2025, which was up 75.18% from $493.3 million recorded in Q2 2025.
  • Over the past 5 years, Cytek Biosciences' Assets peaked at $525.1 million during Q2 2023, and registered a low of $230.3 million during Q2 2021.
  • Moreover, its 5-year median value for Assets was $493.1 million (2022), whereas its average is $480.3 million.
  • As far as peak fluctuations go, Cytek Biosciences' Assets surged by 11400.87% in 2022, and later plummeted by 787.14% in 2024.
  • Cytek Biosciences' Assets (Quarter) stood at $463.3 million in 2021, then grew by 12.12% to $519.5 million in 2022, then decreased by 4.82% to $494.5 million in 2023, then rose by 1.02% to $499.5 million in 2024, then decreased by 0.92% to $494.9 million in 2025.
  • Its Assets stands at $494.9 million for Q3 2025, versus $493.3 million for Q2 2025 and $482.6 million for Q1 2025.